EMAIL THIS PAGE TO A FRIEND

European journal of human genetics : EJHG

Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNA.


PMID 24424122

Abstract

Hereditary diffuse gastric cancer (HDGC) syndrome, although rare, is highly penetrant at an early age, and is severe and incurable because of ineffective screening tools and therapy. Approximately 45% of HDGC families carry germline CDH1/E-cadherin alterations, 20% of which are nonsense leading to premature protein truncation. Prophylactic gastrectomy is the only recommended approach for all asymptomatic CDH1 mutation carriers. Suppressor-tRNAs can replace premature stop codons (PTCs) with a cognate amino acid, inducing readthrough and generating full-length proteins. The use of suppressor-tRNAs in HDGC patients could therefore constitute a less invasive therapeutic option for nonsense mutation carriers, delaying the development of gastric cancer. Our analysis revealed that 23/108 (21.3%) of E-cadherin-mutant families carried nonsense mutations that could be potentially corrected by eight suppressor-tRNAs, and arginine was the most frequently affected amino acid. Using site-directed mutagenesis, we developed an arginine suppressor-tRNA vector to correct one HDGC nonsense mutation. E-cadherin- deficient cell lines were transfected with plasmids carrying simultaneously the suppressor-tRNA and wild-type or mutant CDH1 mini-genes. RT-PCR, western blot, immunofluorescence, flow cytometry and proximity ligation assay (PLA) were used to establish the model, and monitor mRNA and protein expression and function recovery from CDH1 vectors. Cells expressing a CDH1 mini-gene, carrying a nonsense mutation and the suppressor-tRNA, recovered full-length E-cadherin expression and its correct localization and incorporation into the adhesion complex. This is the first demonstration of functional recovery of a mutated causative gene in hereditary cancer by cognate amino acid replacement with suppressor-tRNAs. Of the HDGC families, 21.3% are candidates for correction with suppressor-tRNAs to potentially delay cancer onset.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

GW21186 Anti-CDH1 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB2501665
Anti-CDH1 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2701861
Anti-cdh1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA004812
Anti-CDH1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2104222
Anti-CDH1 antibody produced in rabbit, affinity isolated antibody
SAB4300693
Anti-CDH1 antibody produced in rabbit, affinity isolated antibody
SAB2107370
Anti-CDH1 antibody produced in rabbit, affinity isolated antibody
C7855
Monoclonal Anti-Cdh1 antibody produced in mouse, ~2 mg/mL, clone DCS-266, purified immunoglobulin, buffered aqueous solution
WH0000999M1
Monoclonal Anti-CDH1 antibody produced in mouse, clone 3F4, purified immunoglobulin, buffered aqueous solution
AMAB90862
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1170, purified immunoglobulin, buffered aqueous glycerol solution
AMAB90863
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1172, purified immunoglobulin, buffered aqueous glycerol solution
AMAB90865
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1180, purified immunoglobulin, buffered aqueous glycerol solution
SAB4700237 Monoclonal Anti-CDH1 antibody produced in mouse, clone 67A4, purified immunoglobulin, buffered aqueous solution